Licenses and Collaborations (Details Narrative) - USD ($) $ in Thousands |
12 Months Ended | |
---|---|---|
Dec. 31, 2018 |
Dec. 06, 2018 |
|
Collaboration Agreement [Member] | January 2, 2019 [Member] | ||
Proceeds from collaborators | $ 4,000 | |
Royalty received on sales | $ 156,000 | |
Emory University [Member] | ||
License agreement, description | On December 6, 2018, we notified Emory University ("Emory") of the termination of our License Agreement with Emory, dated March 7, 2013 (the "License Agreement"). Pursuant to the License Agreement, Emory agreed to add to the Licensed Patents and Licensed Technology Emory's rights to any patent, patent application, invention, or technology application that was based on technology disclosed within three (3) years of March 7, 2013. The License Agreement included payments due to Emory ranging from $40,000 to $500,000 based on successful achievement of certain drug development milestones. Additionally, Cocrystal undertook to make royalty payments at 3.5% of net sales due to Emory with a minimum in year one of $25,000 and increase to $400,000 in year five upon product commercialization. | |
Emory University [Member] | License Agreement [Member] | ||
Due from related party | $ 0 | |
Emory University [Member] | Minimum In One Year [Member] | ||
Royalty payment | $ 25 | |
Emory University [Member] | Maximum In Five Year [Member] | ||
Royalty payment | $ 400 | |
Emory University [Member] | Sales Revenue, Net [Member] | ||
Royalty, percentage | 3.50% | |
Emory University [Member] | Minimum [Member] | ||
Payments due to achievement of certain drug development milestones | $ 40 | |
Emory University [Member] | Maximum [Member] | ||
Payments due to achievement of certain drug development milestones | $ 500 |
X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Description of the nature and terms of commitment. No definition available.
|
X | ||||||||||
- Definition Amount of cash outflow for operating activities classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Cash received from collaborators during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|